CYP1A1 and prostate carcinoma: Among individuals from the CYP1A1 GA + GG genotype group (P for interaction, < 0.001), we found there was an association between increased risk of prostate cancer and all three HAA intake groups specifically low (OR, 2.05; 95% CI, 1.19–3.63), intermediate (OR, 1.72; 95% CI, 1.07–2.76), and high (OR, 2.86; 95% CI, 1.83–4.47).